Abstracts tagged "Autoinflammatory Disease"

Abstract Number: 31 • 2017 Pediatric Rheumatology Symposium
Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Nienke M. ter Haar¹, Rianne C. Scholman¹, Wilco de Jager², Nadia Ryter³, Ariane de Ganck⁴, Dirk Foell⁵, Sytze de Roock⁶ and Bas Vastert⁷, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ³BÜHLMANN Laboratories AG, Basel, Switzerland, ⁴Biogazelle NV, Zwijnaarde, Belgium, ⁵Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁶Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease, characterized by fever, rash and arthritis. The IL-1 and IL-6 pathway are crucial in…
Abstract Number: 145 • 2017 Pediatric Rheumatology Symposium
JAK Inhibition Rescues Novel PSMB8 Mutations
J. Brian Shirley¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Allergy, Immunology and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The proteasome associated autoinflammatory syndromes (PRAAS) are characterized by autosomal recessive mutations in the PSMB8 gene. These mutations result in an early childhood overproduction…
Abstract Number: 79 • 2017 Pediatric Rheumatology Symposium
Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases
Jonathan S. Hausmann^1,2, Burcu Guven², Edwin Anderson³ and Fatma Dedeoglu², ¹Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ²Rheumatology, Boston Children's Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Autoinflammatory diseases (AIDs) are a rare group of illnesses characterized by unprovoked episodes of fever and systemic inflammation. An understanding of their pathophysiology has…
Abstract Number: 2384 • 2016 ACR/ARHP Annual Meeting
Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA 2 Deficiency
Antonella Insalaco¹, Gianmarco Moneta², Manuela Pardeo¹, Chiara Passarelli³, Camilla Celani⁴, Virginia Messia⁴ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Roma, Italy, ³Ospedale Pediatrico Bambino Gesù IRCCS, Unit of Medical Genetics, Laboratory of Cytogenetics and Molecular Genetics, Rome, Italy, ⁴Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy
Background/Purpose: The deficiency of adenosindeaminase 2 (DADA2) is a recently described autosomal recessive autoinflammatory disease, caused by mutations of CECR1 and characterized by early onset…
Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting
Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Hanna Kim¹, Terrance P. O'Hanlon², Adriana Almeida de Jesus³, Yan Huang³, Ira N. Targoff^4,5, Frederick W. Miller², Raphaela Goldbach-Mansky⁶ and Lisa G. Rider², ¹NIAMS/NIH, Bethesda, MD, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity. Clinical features vary among myositis-specific autoantibody…
Abstract Number: 2429 • 2016 ACR/ARHP Annual Meeting
Mechanisms for the Development of Lung Fibrosis in Sting-Associated Vasculopathy with Onset in Infancy (SAVI)
Adriana Almeida de Jesus¹, Louise Malle¹, Dan Yang², Bernadette Marrero¹, Yin Liu³, Gina A. Montealegre Sanchez¹, Dawn C. Chapelle⁴, Hanna Kim⁴, Michelle O'Brien⁴, Gregor Dueckers⁵, Suzanne Ramsey⁶, Joseph R. Fontana⁷, Steven M. Holland⁸, Yan Huang¹, Suvimol Hill⁹, Laisa Santiago¹⁰, Benito Gonzalez¹¹, Paul Brogan¹², Juergen Brunner¹³, Ebun Omoyinmi¹⁴, Athimalaipet V Ramanan¹⁵, Amy Paller¹⁶, Olcay Y. Jones¹⁷, Seza Ozen¹⁸, Stephen Brooks⁴, Zuoming Deng⁴, Manfred Boehm¹⁹, Raphaela Goldbach-Mansky²⁰ and Helmut Wittkowski²¹, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ³Scientific Review Branch, NIAMS, NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, MD, ⁵Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Krefeld, Germany, ⁶Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁷Cardiovascular and Pulmonary Branch, NHLBI, NIH, Bethesda, MD, ⁸Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, MD, ⁹Radiology Department, Clinical Center, NIH, Bethesda, MD, ¹⁰Johns Hopkins All Children's Hospital Rheumatology, Saint Petersburg, FL, ¹¹Luis Calvo Mackenna Hospital, Santiago, Chile, ¹²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹³Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria, ¹⁴University College London Institute of Child Health, London, United Kingdom, ¹⁵University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ¹⁶Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA;, Chicago, IL, ¹⁷Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ¹⁹Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ²⁰Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²¹Department of Pediatric Rheumatology and Immunology, University Hospital of Muenster, Münster, Germany
Background/Purpose: STING-Associated Vasculopathy with Onset in Infancy (SAVI) is a monogenic autoinflammatory interferonopathy caused by gain-of-function mutations in TMEM173/STING, a nucleic acid sensor adaptor linked…
Abstract Number: 2430 • 2016 ACR/ARHP Annual Meeting
Mutations in the Tyrosine-Protein Kinase Lyn Cause an Early-Onset Neutrophilic Vasculitis Syndrome
Adriana Almeida de Jesus¹, Gina A. Montealegre¹, Helen Freeman², Neil Martin³, Ebun Omoyinmi⁴, Bernadette Marrero¹, Katherine R. Calvo⁵, Chyi-Chia Richard Lee⁶, April D. Brundidge⁷, David Kleiner⁸, Stephen Hewitt⁸, Dawn C. Chapelle⁷, Yan Huang¹, Nirali Shah⁸, Stephen Brooks⁷, Eric Meffre⁹, Paul Brogan¹⁰, Hyesun Kuehn¹¹, Sergio Rosenzweig¹², Melinda Merchant⁸, Zuoming Deng⁷, Susan Moir¹³ and Raphaela Goldbach-Mansky¹⁴, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²Raigmore Hospital, Inverness, United Kingdom, ³Royal Hospital for Children, Glasgow, United Kingdom, ⁴University College London Institute of Child Health, London, United Kingdom, ⁵Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, ⁶Dermatopathology Section, Laboratory of Pathology, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD, ⁸National Cancer Institute, NIH, Bethesda, MD, ⁹Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ¹⁰UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, ¹²Department of Laboratory Medicine/NIH, Bethesda, MD, ¹³National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁴Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Tyrosine-protein kinase Lyn is a Src-family tyrosine kinase expressed by hematopoietic and non-hematopoietic cell types. Phosphorylation of a tyrosine residue at position 508 renders…
Abstract Number: 2431 • 2016 ACR/ARHP Annual Meeting
Characterization of Innate Immune Cells in Patients with the Interferon-Mediated Autoinflammatory Diseases Sting Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE)
Bernadette Marrero¹, Yin Liu², Katherine R. Calvo³, Angelique Biancotto⁴, Yan Huang¹, Adriana Almeida de Jesus¹, Gina A. Montealegre Sanchez¹ and Raphaela Goldbach-Mansky⁵, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²Scientific Review Branch, NIAMS, NIH, Bethesda, MD, ³Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, ⁴Center for Human Immunology, Autoimmunity and Inflammation, NHLBI/NIH, Bethesda, MD, ⁵Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: We recently described two rare autoinflammatory interferonopathies, STING Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and…
Abstract Number: 2432 • 2016 ACR/ARHP Annual Meeting
Immune Abnormalities Leading to Exaggerated Production of IFN-Gamma (IFNγ) and the Therapeutic Response to an Anti-IFNγ Antibody in a Patient with NRLC4 Mediated Disease
Claudia Bracaglia¹, Giusi Prencipe², Manuela Pardeo¹, Geneviève Lapeyre³, Emiliano Marasco², Antonella Insalaco¹, Walter Ferlin³, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland
Background/Purpose: Animal and human data suggest that IFNγ plays a pathogenic role in HLH. A phase 2 trial with the anti-IFNγ monoclonal antibody NI-0501 in…
Abstract Number: 3208 • 2016 ACR/ARHP Annual Meeting
Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”,“Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases
Gina A. Montealegre Sanchez¹, Adam Reinhardt², Paul Brogan³, Dawn C. Chapelle⁴, Hanna Kim⁴, Samantha Judd⁴, Bahar Kost⁴, Michelle O'Brien⁴, Wendy Goodspeed⁵, Robert A. Colbert⁴, Meryl Waldman⁶, Deborah L. Stone⁷, Ling Gao⁸, JA Dare⁸, Susanne Schalm⁹, Thomas L. Klausmeier¹⁰, Sara Murias¹¹, Yackov Berkun¹², Diane Brown¹³, John D. Carter¹⁴, Fehime K Eroglu¹⁵, A. Zlotogorski¹⁶, Philip Hashkes¹⁷, Helmut Wittkowski¹⁸, Suzanne Ramsey¹⁹, Seza Ozen²⁰, Adriana Almeida de Jesus²¹ and Raphaela Goldbach-Mansky²², ¹NIAID/NIH, Bethesda, MD, ²Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, ³UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴NIAMS/NIH, Bethesda, MD, ⁵Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁶NIDDK/NIH, Bethesda, MD, ⁷NHGRI/NIH, Bethesda, MD, ⁸University of Arkansas for Medical Sciences, Little Rock, AR, ⁹LMU Munich, Munich, Germany, ¹⁰Riley Hospital for Children, Indianapolis, IN, ¹¹Hospital Infantil La Paz, Madrid, Spain, ¹²Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹³Children's Hospital Los Angeles, Los Angeles, CA, ¹⁴Division of Rheumatology, University of South Florida, Tampa, FL, ¹⁵Department of Pediatrics, Hacettepe University Hospitals, Ankara, Turkey, ¹⁶Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹⁷Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ¹⁸Pediatrics, University of Muenster, Muenster, Germany, ¹⁹Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁰Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²²Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Chronically elevated serum IP-10 (CXCL10) levels, and a prominent “interferon (IFN)-response gene signature” in patients with chronic neutrophilic dermatosis with lipodystrophy and elevated temperatures…
Abstract Number: 254 • 2016 ACR/ARHP Annual Meeting
NLRP12 Autoinflammatory Disease: A Chinese Case Series and Literature Review
Min Shen¹, Lin Tang², Xiaochun Shi³, Xiaofeng Zeng¹ and Qingping Yao⁴, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China, ³Infectious Disease, Peking Union Medical College Hospital, Beijing, China, ⁴Rheumatology, Allergy, and Immunology, Stony Brook University School of Medicine, Stony Brook, NY
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) are a genetically heterogeneous group of rheumatic diseases that are driven by abnormal activation of the innate immune system.…
Abstract Number: 255 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Long-Term Canakinumab Therapy in Patients with CAPS: Final Results from Beta-Confident Registry
Hal M. Hoffman¹, Jasmin B. Kuemmerle-Deschner², Philip N. Hawkins³, Tom van der Poll⁴, Ulrich A. Walker⁵, Antonio Speziale⁶, Yolandi Joubert⁶ and Hugh H. Tilson⁷, ¹Division of Rheumatology, Allergy, and Immunology, University of California at San Deigo, La Jolla, CA, ²Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ³University College London Medical School, London, United Kingdom, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is a rare auto-inflammatory disease encompassing a spectrum of 3 phenotypes: familial cold auto-inflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS), and…
Abstract Number: 257 • 2016 ACR/ARHP Annual Meeting
CNS Manifestations of Patients with Muckle-Wells Syndrome
sara Sebnem KILIC¹, sukru cekic² and Juan Aróstegui³, ¹Pedaitric Rheumatology, Prof Dr, Bursa, Turkey, ²Dr, Bursa, Turkey, ³Prof, Barcelona, Spain
Background/Purpose: CAPS is a rare autoinflammatory disease associated with mutations in the NLRP3 gene that result in overactivation of the inflammasome, increased secretion of IL-1beta…
Abstract Number: 258 • 2016 ACR/ARHP Annual Meeting
Unmet Psychosocial Needs in Patients with CAPS
Jasmin B. Kuemmerle-Deschner¹, Gabi Erbis¹, Tetiana Sergiichuk¹, Sandra Hansmann¹, Iris Haug¹ and Susanne Benseler², ¹Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ²Pediatrics, University of Calgary, Calgary, AB, Canada
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease. Generalized manifestations like recurrent fever and fatigue and organ disease like reduced vision, hearing loss,…
Abstract Number: 1005 • 2016 ACR/ARHP Annual Meeting
Biallelic Hypomorphic Mutations in a Linear Deubiquitinase Define Otulipenia, an Early-Onset Systemic Autoinflammatory Disease
Qing Zhou¹, Xiaomin Yu², Erkan Demirkaya³, Natalie Deuitch⁴, Deborah L. Stone⁵, Wanxia L. Tsai⁶, Hongying Wang⁷, Yong Hwan Park⁷, Amanda K. Ombrello⁸, Tina Romeo⁴, Elaine F. Remmers⁴, JaeJin Chae⁹, Massimo G. Gadina¹⁰, Steven B. Welch¹¹, Seza Ozen¹², Rezan Topaloglu¹³, Mario Abinun¹⁴, Daniel L. Kastner⁷ and Ivona Aksentijevich⁸, ¹Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, Bethesda, MD, ³Gulhane Military Medical Academy, FMF Arthritis Vasculitis and Orphan disease Research Center (FAVOR), Ankara, Turkey, ⁴National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁷National Human Genome Research Institute, Bethesda, MD, ⁸Inflammatory Disease Section, NHGRI, National Institutes of Health, Bethesda, MD, ⁹Inflammatory disease section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ¹⁰[email protected], Bethesda, MD, ¹¹Heart of England NHS Foundation Trust, Birmingham, United Kingdom, ¹²Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹³Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁴Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom
Background/Purpose: Autoinflammatory diseases are caused by mutations in genes regulating innate immune responses. More than 20 genes have been associated with various monogenic autoinflammatory disorders.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].